
TheraPanacea
Empowering Artificial Intelligence towards Precision Medicine
TheraPanacea is an innovative information technology company devoted to unlocking the power of AI-based solutions to drive innovation in healthcare.
A spin-off of University Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge.
Today, ART-PlanTM, TheraPanacea dedicated suite for radio-oncology, is used by more than 60 cancer centres across Europe, Africa, Middle-East and the US and is helping to improve care for more than 60,000 patients every year.
TheraPanacea also develops and operates the ART-OmicsTM platform enabling pharmaceutical companies to accelerate clinical research by harnessing AI-based multi-modality biomarker discovery in clinical trials and their effective integration within the clinical workflow at scale in the form of certified medical devices.
Adaptive radiotherapy solution, cancer care AI, contouring software
Reinventing cancer care through AI - Innovating technology to standardize cancer treatment planning - Adaptive radiotherapy solution